{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:06:59Z","timestamp":1793200019010,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2020R1I1A3071938"],"award-info":[{"award-number":["NRF-2020R1I1A3071938"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2025-RISE-11-003-03"],"award-info":[{"award-number":["2025-RISE-11-003-03"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003081","name":"Ministry of Education, Ethiopia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118799","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:08:24Z","timestamp":1763701704000},"page":"118799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of recombinant Mesozumab-CPTin that dual-targets mesothelin and CP2c for anticancer therapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Boram","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Tae","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbeom","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-5949","authenticated-orcid":false,"given":"DongSun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Bong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-5354","authenticated-orcid":false,"given":"Hyung-Sik","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-4898","authenticated-orcid":false,"given":"So Yeong","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118799_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer Groups From 2010 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"8","author":"Global Burden of Disease Cancer","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118799_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.biopha.2025.118799_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.biopha.2025.118799_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118799_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118799_bib7","article-title":"Targeting mesothelin in cancer","volume":"31","author":"Elbi","year":"2023","journal-title":"Mol. Ther. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118799_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11912-023-01367-8","article-title":"Targeting mesothelin in solid tumours: anti-mesothelin antibody and drug conjugates","volume":"25","author":"Chu","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"33","key":"10.1016\/j.biopha.2025.118799_bib10","article-title":"A cell-penetrant peptide disrupting the transcription factor CP2c complexes induces cancer-specific synthetic lethality","volume":"10","author":"Son","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"12","key":"10.1016\/j.biopha.2025.118799_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126369","article-title":"Structural and functional insights into CP2c transcription factor complexes","volume":"23","author":"Son","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1535-7163.MCT-14-0366","article-title":"Tumor-penetrating iRGD peptide inhibits metastasis","volume":"14","author":"Sugahara","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118799_bib13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1742-4658.2005.04564.x","article-title":"Identification and characterization of four novel peptide motifs that recognize distinct regions of the transcription factor CP2","volume":"272","author":"Kang","year":"2005","journal-title":"FEBS J."},{"issue":"12 Pt 1","key":"10.1016\/j.biopha.2025.118799_bib14","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"550","key":"10.1016\/j.biopha.2025.118799_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7252","article-title":"Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118799_bib16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"Ho","year":"2011","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.biopha.2025.118799_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib20","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/annonc\/12.suppl_1.S57","article-title":"G. International Herceptin Study, Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann. Oncol."},{"issue":"10200","key":"10.1016\/j.biopha.2025.118799_bib21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118799_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-60327-058-8_19","article-title":"Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multiangle or static light scattering","volume":"426","author":"Nettleship","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118799_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123407","article-title":"Recombinant protein expression: challenges in production and folding related matters","volume":"233","author":"Beygmoradi","year":"2023","journal-title":"Int J. Biol. Macromol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118799_bib25","first-page":"4235","article-title":"High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis","volume":"13","author":"Hagerty","year":"2023","journal-title":"Am. J. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118799_bib27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41417-024-00816-1","article-title":"Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer","volume":"31","author":"Malla","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.118799_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101508","article-title":"Development of an anti-HER2 single-chain variable antibody fragment construct for high-yield soluble expression in escherichia coli and one-step chromatographic purification","volume":"13","author":"Byun","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118799_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2859-7-11","article-title":"Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview","volume":"7","author":"Gasser","year":"2008","journal-title":"Micro Cell Fact."},{"issue":"14 Pt 1","key":"10.1016\/j.biopha.2025.118799_bib32","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-07-1179","article-title":"Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling","volume":"14","author":"Yang","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12885-024-11998-0","article-title":"MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival","volume":"24","author":"Moliere","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118799_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111899","article-title":"The paradoxical role of matrix metalloproteinase-11 in cancer","volume":"141","author":"Ma","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118799_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"6","key":"10.1016\/j.biopha.2025.118799_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500993X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500993X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:55:47Z","timestamp":1777013747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500993X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S075333222500993X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118799","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of recombinant Mesozumab-CPTin that dual-targets mesothelin and CP2c for anticancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118799"}}